News

Overall survival was prolonged with the addition of darolutamide to androgen-deprivation therapy and docetaxel in patient with metastatic, hormone-sensitive prostate cancer.

The phase 2/3 RINGSIDE clinical trial of AL102 has reached a key enrollment milestone.

The MARIPOSA study seeks to assess efficacy, safety, and pharmacokinetics of the combination of amivantamab-vmjw and lazertinib in locally advanced, or metastatic non-small cell lung cancer.

In an interview with Targeted Oncology, Annelise Wilhite, MD, discussed the findings of a clinical investigation of survival in patients with vulvar/vaginal melanomas.

Thomas Habermann, MD, discusses R-CHOP and how it can be improved upon as a treatment method for diffuse large B-cell lymphoma.

A reduction in cabozantinib dosage because of toxicity shows improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

The collaboration between AON and VieCure is designed to facilitate the delivery of precision oncology and personalized care and treatment for patients across the ever-expanding AON network.

Data supporting zanubrutinib for the treatment of chronic lymphocytic leukemia or small lymphocytic leukemia will undergo a regular FDA review in consideration for FDA approval.

The FDA has approved FoundationOne CDx as a companion diagnostic to pembrolizumab for patients with microsatellite instability high solid tumors.

Richard Silver, MD, discusses the Interferon Initiative organized by the Myeloproliferative Neoplasm Research Foundation.

Significant survival improvement has been shown with trastuzumab deruxtecan in patients with HER2-low breast cancer treated in the DESTINY-Breast04 clinical trial.

In an interview with Targeted Oncology, Tanios S. Bekaii-Saab, MD, explained how adagrasib works to target KRAS mutations as well as its importance.

Vivek Subbiah discusses the phase 1/2 LIBRETTO-001 study which sought to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of selpercatinib in patients with advanced solid tumors.

BOS172738 shows promising results in the treatment of RET gene altered medullary thyroid cancer and non–small cell lung cancer, according to a phase 1 study.

In an interview with Targeted Oncology, Vitaly Margulis, MD, discussed the function and findings of metabolomics in renal cell carcinoma.

Results from a retrospective study favor younger matched unrelated donors for consideration in the donor selection for patients with myelodysplastic syndrome.

Srdan Verstovsek, MD, discussed maintaining hematocrit levels in patients with polycythemia vera as well as research on the use of rusfertide.

Bradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.

SWOG 1318 results are promising for extended blinatumomab use in patients with acute lymphoblastic leukemia.

A subgroup analysis of lenvatinib plus pembrolizumab showed similar results to the global population of patients with advanced renal cell carcinoma who participated in the phase 3 CLEAR trial.

Golidocitinib is showing promise for the treatment of relapsed or refractory peripheral T-cell lymphoma in an ongoing phase 1/2 clinical trial.

Rana R. McKay, MD, discusses KEYNOTE-564 and the future of adjuvant immunotherapy in renal cell carcinoma.

IO-202 for the treatment of patients with relapsed or refractory acute myeloid leukemia is a strategy under investigation in a phase 1, multicenter, open-label, dose-escalation and expansion study.

The FDA will conduct a speedy review of the supplemental biologics license application for lisocabtagene maraleucel as second-line treatment for adult patients with relapsed or refractory large B-cell lymphoma.

A phase 2 trial sought to evaluate the efficacy and safety of the combination of anlotinib and sintilimab in patients with recurrent advanced endometrial cancer.

Following a report of low CD4-positive T cell counts in a patient’s peripheral blood, the FDA placed a clinical hold on a phase 1 study of LB1901.

Treatment of indolent mantle cell lymphoma tumors may require an individualize approach, but frontline ibrutinib and rituximab is one possibility.

The FDA has accepted a new drug application for adagrasib for the treatment of patients with non-small cell lung cancer harboring KRAS G12C mutation.

Cancer Treatment Centers of America Phoenix, has achieved Magnet recognition by the American Nurses Credentialing Center.

In an interview with Targeted Oncology, Jorge Nieva, MD, provided a recap of the recent ODAC meeting and explained his stance against further research for frontline sintilimab plus chemotherapy for the treatment of patients with nonsquamous NSCLC.